Then, DCs acquire high capability to migrate, to phagocytose dying cells, to process more efficiently caspase-cleaved cellular proteins (i.e., NM-neoAgs), and to cross-prime CD8+ T cells that can provide tumor control35,38,41,42, on the one hand, and immunopathology in various forms of chronic inflammatory diseases, on the other hand37,43–48. Here, CD8A is linked to neoplasm.